Table 1 Baseline characteristics of study population
Variables | CoronaVac vaccines (n = 93) | Convalescent cohort 1 (n = 15) | Convalescent cohort 2 (n = 5) |
|---|---|---|---|
Age (years, median (P25, P75)) | 34 (28, 40) | 50 (28, 59) | 30 (27, 31) |
Age group (years, n, %) | |||
 21–30 | 34 (36.6%) | 3 (20.0%) | 2 (40.0%) |
 31–40 | 36 (38.7%) | 3 (20.0%) | 3 (60.0%) |
 41–50 | 15 (16.1%) | 3 (20.0%) | 0 (%) |
 51–60 | 8 (8.6%) | 6 (40.0%) | 0 (%) |
Gender (n, %) | |||
 Male | 33 (35.5%) | 7 (46.7%) | 1 (20.0%) |
 Female | 60 (64.5%) | 8 (53.3%) | 4 (80.0%) |
Interval between 1st dose and 2nd dose (days) | |||
 Median (IQR) | 21 (17.3, 22.4) | NA | 45 (42.8, 47.2) |
Interval between 2nd dose and 3rd dose (months) | |||
 Median (IQR) | 8.6 (8.1, 8.7) | NA | NA |
Seroconversion (%) | |||
 IgG after 2 doses | 97.8% | 100%* | NA |
 Surrogate Nab after 2 doses | 98.9% | 100%* | NA |
 IgG after 3 doses | 100% | NA | 100%* |
 Surrogate Nab after 3 doses | 100% | NA | 100%* |
Comorbidities (n, %) | 2 (2.1%) | 0 (%) | 0 (%) |